Neurimmune and Ethris have teamed up to develop an inhaled, mRNA-based antibody treatment for COVID-19.
The immunotherapy would produce therapeutic antibodies in the lungs of affected patients. The companies are conducting joint research and development activities and sharing costs.
They expect to begin manufacturing the investigational drug for clinical trials this summer. Clinical testing is expected to begin in the fourth quarter of 2020.